Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Subscribe To Our Newsletter & Stay Updated
